Please login to the form below
Ariad Pharma
This page shows the latest Ariad Pharma news and features for those working in and with pharma, biotech and healthcare.
Takeda rebels take aim at Shire acquisition
of bolt-on acquisitions and licensing deals, including the $5.2bn takeover of cancer company Ariad Pharma.
Latest news
-
Takeda's gamble on Ariad pays off with Alunbrig approval
ALK-inhibitor will treat NSCLC patients as second-line therapy. Takeda took a chance a few weeks ago when it acquired Ariad with lead pipeline prospect Alunbrig still under regulatory review ... Takeda agreed to buy Ariad earlier this year in a $5.2bn
-
Ariad files early marketing application for brigatinib
Ariad has filed for approval in the US for brigatinib - its second drug - after positive results in lung cancer were reported at the ASCO conference. ... On Friday, the company announced it had licensed Latin American distribution rights to Pint Pharma
-
Angelini to market Ariad’s Iclusig in Eastern Europe
Comes after leukaemia drug passes EMA safety review. US pharma company Ariad Pharmaceuticals has licensed its cancer drug Iclusig to Italy-based firm Angelini Pharma to market in 23 Eastern European ... Angelini will handle all sales and marketing
-
Ariad cuts 160 jobs in US after Iclusig suspension
As such, Ariad's job cuts only affect the US, with European roles unaffected. ... Following the reduction, Ariad will be left with 295 employees covering both regions.
-
Ariad tanks as Iclusig trial is halted on safety grounds
Shares fall after leukaemia patients develop blood clots. . Investors continued to bail out of Ariad Pharmaceuticals after it was forced to terminate a pivotal trial of its leukaemia drug Iclusig because ... on the market (albeit with more restrictive
More from news
Approximately 1 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Ariad appoints new CEO
Paris Panayiotopoulos joins the US biotech from EMD Serono. Paris Panayiotopoulos has moved from EMD Serono to join Ariad as its new president and CEO. ... Panayiotopoulos said: “I am very pleased to be joining ARIAD at this exciting time.
-
Ariad founder Harvey Berger to retire as CEO and chairman
Effective from December 31 or upon finding of successor. Ariad Pharmaceuticals founder Harvey J. ... Marty Duvall, executive VP and chief commercial officer at Ariad, added: “Harvey enthusiastically embraced the evolution of ARIAD into a global
-
Ariad appoints new board member
Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib). ... Ariad also announced that another director is due to join the board, bringing the total number of board members to 10.
-
Jonathan Dickinson joins Ariad from BMS
Will lead launch of chronic myeloid leukaemia treatment Iclusig. Ariad Pharmaceuticals has appointed Bristol-Myers Squibb's (BMS) Jonathan Dickinson as general manager of its European business. ... He joins at an important time for Ariad in Europe as it
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
How to integrate data to drive sales
Inspired by a recent Agnitio roundtable discussion with Allergan, Ariad Pharmaceuticals, Astellas and Ipsen Pharma. As the number of our digital channels and tools continually expand, there are many opportunities to
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- US secures 100 million doses of Sanofi/GSK’s COVID-19 vaccine
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- Roche’s Tecentriq combo scores FDA approval for melanoma
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Artificial Intelligence in Digital Therapeutics
- Virtual Reality in Medicine and Clinical Research
- J&J inks $1bn deal with US for coronavirus vaccine
- Novartis builds its case for novel MS treatment ofatumumab
- Pfizer’s Xalkori follow-up Lorbrena hits the mark in first-line lung cancer
- Award-winning agency Porterhouse Medical Group joins imc group with Waterland Private Equity’s support
PMHub
EPG Health
REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
